8-K: Carisma Therapeutics Prioritizes CT-0525, Reports 2023 Financial Results and Restructures Operations

Carisma Therapeutics is prioritizing its CT-0525 program, pausing development of CT-1119, and restructuring operations, including a 37% workforce reduction, to extend its cash runway into the third quarter of 2025.

Summary

• Carisma Therapeutics announced its fourth quarter and full year 2023 financial results, along with a business update.
• The company is prioritizing the development of CT-0525, an anti-HER2 CAR-Monocyte therapy, due to its potential for increased exposure compared to CT-0508.
• Carisma will cease further development of CT-0508 and CT-1119, pending additional financing.
• The company's cash and cash equivalents were $77.6 million as of December 31, 2023.
• A restructuring plan, including a 37% workforce reduction in the second quarter of 2024, is expected to extend the company's cash runway into the third quarter of 2025.
• Research and development expenses for the full year 2023 were $74.1 million, compared to $56.6 million in 2022.
• General and administrative expenses for the full year 2023 were $29.5 million, compared to $9.4 million in 2022, with a significant portion due to non-recurring merger costs.
• The net loss for 2023 was $86.9 million, compared to $61.2 million in 2022.
• The first patient in the CT-0525 Phase 1 clinical study is expected to be treated in the second quarter of 2024, with initial data expected by year-end 2024.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The prioritization of CT-0525 and the extended cash runway are positive, but the workforce reduction, increased losses, and pausing of CT-1119 development are negative. The overall sentiment is cautiously optimistic with significant risks.

Positives

• The company is prioritizing CT-0525, which has the potential for a 2,000-fold increase in total exposure compared to CT-0508.
• The company has a clear plan to extend its cash runway into the third quarter of 2025 through cost-cutting measures.
• The company expects to treat the first patient in the CT-0525 Phase 1 clinical study in the second quarter of 2024.
• The company has a collaboration with Moderna for in vivo CAR-M development.
• Pre-clinical data from the fibrosis program is targeted for the second quarter of 2024.

Negatives

• The company is pausing development of CT-1119, pending additional financing.
• The company is reducing its workforce by approximately 37%.
• The company reported a net loss of $86.9 million for 2023, an increase from $61.2 million in 2022.
• General and administrative expenses increased significantly in 2023 due to merger-related costs.

Risks

• The company's ability to obtain additional financing to continue development of CT-1119 is uncertain.
• The restructuring plan, including a significant workforce reduction, could impact the company's operations.
• The company's ability to achieve positive results in clinical trials for CT-0525 is not guaranteed.
• The company's expenses may increase again in future years as it advances clinical trials.
• The company is subject to risks related to regulatory approvals and intellectual property protection.

Future Outlook

Carisma anticipates that its cash and cash equivalents, combined with cost savings from the revised operating plan, are sufficient to sustain its planned operations into the third quarter of 2025. The company expects to treat the first patient in the CT-0525 Phase 1 clinical study in the second quarter of 2024 and to report initial data from the study by year-end 2024.

Management Comments

• Steven Kelly, President and Chief Executive Officer of Carisma, stated that the company is prioritizing CT-0525 due to its potential to be a significant advancement in CAR-M treatment.
• Mr. Kelly also mentioned that the company has undertaken a careful review of its business and prioritized pipeline programs with the greatest overall potential and near-term milestones.
• Mr. Kelly expressed gratitude to those impacted by the workforce reduction for their contributions to the company's mission.

Industry Context

This announcement reflects a trend in the biopharmaceutical industry where companies are focusing resources on their most promising programs and streamlining operations to extend their cash runway. The prioritization of CT-0525 aligns with the growing interest in CAR-T and CAR-M therapies for solid tumors.

Comparison to Industry Standards

• Carisma's decision to prioritize CT-0525, a CAR-Monocyte therapy, is in line with the industry's move towards more effective cell therapies for solid tumors, similar to companies like Allogene Therapeutics and Kite Pharma who are also exploring novel cell therapy approaches.
• The company's cash runway into the third quarter of 2025 is a common goal for clinical-stage biotechs, and the restructuring plan is a typical response to financial pressures, similar to actions taken by companies like Adaptimmune and bluebird bio.
• The increase in R&D expenses is expected for a company advancing clinical trials, but the significant increase in G&A expenses due to merger costs is not typical and may be a concern for investors, similar to the challenges faced by companies after mergers like Juno Therapeutics and Celgene.
• The net loss of $86.9 million is substantial, but not uncommon for a clinical-stage biotech company, and is comparable to losses reported by companies like CRISPR Therapeutics and Editas Medicine.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased losses and workforce reduction, but may be encouraged by the prioritization of CT-0525 and the extended cash runway.
• Employees will be significantly impacted by the 37% workforce reduction.
• Patients may benefit from the development of CT-0525, but the pausing of CT-1119 development may be a setback for some.
• Suppliers and creditors may be impacted by the company's restructuring plan.

Next Steps

• The company will treat the first patient in the CT-0525 Phase 1 clinical study in the second quarter of 2024.
• The company will report initial data from the CT-0525 Phase 1 study by year-end 2024.
• The company will report data from the CT-0508 and pembrolizumab substudy in the second quarter of 2024.
• The company will implement a 37% workforce reduction in the second quarter of 2024.
• The company will continue to advance its in vivo CAR-M collaboration with Moderna.
• The company will release pre-clinical proof of concept data from the fibrosis program in the second quarter of 2024.

Key Dates

Keywords

CAR-T, CAR-M, Immunotherapy, Oncology, Biopharmaceutical, CT-0525, CT-0508, CT-1119, HER2, Clinical Trial, Restructuring, Financial Results